

Success of Acticor Biotech's Initial Public Offering on the Euronext Growth® market, with €15.5 million raised

- **Offering price set at €7.12 per share**
- **Capital increase of €15.5 million**
- **Global demand of €15.5 million at the offering price (€13.4 million in the Global Placement and €2.1 million in the Open Price Offer)**
- **Settlement-delivery scheduled for October 29, 2021 and shares scheduled to begin trading on the Euronext Growth® market in Paris on November 1, 2021**
- **Funds raised to better treat stroke and reduce disability**

Paris, France, October 27, 2021– **ACTICOR BIOTECH** (ISIN: FR00140050J5 – ALACT), a clinical stage biopharmaceutical company specialized in the development of drugs for treating cardiovascular emergencies, today announces the success of its Initial Public Offering on the Euronext Growth market in Paris.

Gilles AVENARD, Chief Executive Officer of Acticor Biotech, states: *“On behalf of the entire team, I would like to thank our historical shareholders who took part in this transaction and to the new shareholders who enabled it to be a success. Thanks to these funds, it is with determination that we will be able to accelerate our clinical developments in the treatment of cardiovascular emergencies, which remain a crucial public health challenge. We are proud to be one of the few listed companies in the world which specializes in developing a new drug for ischemic strokes. This focus makes ACTICOR a unique investment vehicle for our shareholders, and we will do everything we can to successfully meet the next stages of our developments”*.

Reminder of the purpose of the Offering

The funds raised will allow the Company to continue its Research and Development operations in view of its objective to commercialize its product under development, glenzocimab. The estimated net proceeds of the issuance of the New Shares, i.e. approximately €12.3 million, will be allocated as follows:

- 62% to clinical research, and notably the continuation of the product's clinical development, the financing of part 1 of ACTISAVE through to the futility analysis and the start of Phases 2 of both BREATH and LIBERATE;
- 20% to the production, pharmaceutical and non-clinical development of glenzocimab; and
- 18% to running costs, general expenses and intellectual property expenses.

Reminder of the subscription commitments totaling €10.3 million

ACTICOR BIOTECH received subscription commitments from its historical shareholders (including Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Mirae Asset Capital and Mediolanum farmaceutici) totaling €10.3 million.

Results and allocation of the Offering

Offering Price

The price set for the Global Placement (the “**Global Placement**”) and the Open Price Offer (the “**Open Price Offer**” or “**OPO**”) and, together with the Global Placement, the “**Offering**”) is €7.12 per share, at the the lower end of the indicative offering price range.

Size of the Offering

The initial public offering enables the Company to carry out a capital increase of €15.5 million via the issuance of 2,178,176 new ordinary shares.

The 2,178,176 new shares subscribed within the framework of the Offering have been allocated as follows:

- **Global Placement:** 1,883,952 shares allocated to institutional investors (i.e. 86.5% of the total number of shares issued);
- “**OPO**” **Open Price Offer:** 294,224 shares allocated to the public (i.e. 13.5% of the total number of shares issued).

Based on the Offering Price of 7.12 euros per share and the 8,367,600 existing shares, Acticor Biotech's market capitalization is approximately €75.1 million following the transaction.

The over-allotment option will not be exercised. No stabilization operations will therefore be implemented.

A liquidity provider agreement with Kepler Cheuvreux will enter into force from the first day of trading scheduled for November 1, 2021, it being specified that an amount of €600,000 in cash will be allocated to the liquidity account within the framework of this agreement.

Settlement and delivery of the OPO and Global Placement is scheduled for October 29, 2021, and trading in Acticor Biotech shares on the Euronext Growth market in Paris is scheduled to begin on November 1, 2021.

Breakdown in share capital

Following the IPO, the breakdown in Acticor Biotech's share capital is as follows:

| Shareholders | Before the IPO* | | After the IPO* | |
|--|------------------------|--------------------------------------|------------------------|--------------------------------------|
| | Total number of shares | % of share capital and voting rights | Total number of shares | % of share capital and voting rights |
| Mr. Gilles Avenard | 142,260 | 1.70% | 143,664 | 1.36% |
| Mr. Alain Munoz | 0 | 0.00% | 0 | 0.00% |
| Mr. Jean-Pierre Cazenave | 0 | 0.00% | 1,404 | 0.01% |
| Mr. Yannick Pletan | 0 | 0.00% | 0 | 0.00% |
| Mrs. Sophie Binay | 0 | 0.00% | 0 | 0.00% |
| FPCI CAP DECISIF 3 | 860,520 | 10.28% | 925,530 | 8.78% |
| NEWTON BIO CAPITAL I PRICAF PRIVEE SA | 1,090,900 | 13.04% | 1,556,480 | 14.76% |
| GO CAPITAL AMORCAGE II | 556,280 | 6.65% | 690,582 | 6.55% |
| MEDIOLANUM FARMACEUTICI S.p.A | 2,009,100 | 24.01% | 2,360,222 | 22.38% |
| MIRAE ASSET CELLTRION NEW GROWTH FUND I | 363,640 | 4.35% | 447,909 | 4.25% |
| A&B (HK) LIMITED | 592,600 | 7.08% | 733,049 | 6.95% |
| Total directors and executive officers | 5,615,300 | 67.11% | 6,858,840 | 65.04% |
| PRIMER CAPITAL I LP | 73,160 | 0.87% | 73,160 | 0.69% |
| CMS MEDICAL VENTURE INVESTMENT (HK) LIMITED | 592,600 | 7.08% | 733,049 | 6.95% |
| Total investment funds | 665,760 | 7.96% | 806,209 | 7.64% |
| Objectif Acticor | 370,500 | 4.43% | 370,500 | 3.51% |
| Objectif Acticor 2 | 305,400 | 3.65% | 305,400 | 2.90% |
| Mr. Philippe Billiald | 270,600 | 3.23% | 270,600 | 2.57% |
| Mrs. Martine Jandrot-Perrus | 244,200 | 2.92% | 245,604 | 2.33% |
| Others | 895,840 | 10.71% | 954,326 | 9.05% |
| Total other minority shareholders | 2,086,540 | 24.94% | 2,146,430 | 20.35% |
| Free float | 0 | 0 | 734,297 | 6.96% |
| TOTAL | 8,367,600 | 100.00% | 10,545,776 | 100.00% |

*: On a non-diluted basis

Liquidity contract

Acticor Biotech has mandated Kepler Cheuvreux to act as liquidity provider, pursuant to a liquidity provider agreement in respect of Acticor Biotech shares on the Euronext Growth market starting, from the first day of listing scheduled for November 1, 2021. Within the framework of this agreement, an amount of €600,000 in cash has been allocated to the liquidity account. The announcement of the entry into force of this contract and the description of the Company's share buyback program will be made in a separate press release published prior to the listing of the shares. This contract has been drawn up in accordance with current legislation, and notably with AMF Decision n° 2021-01 of June 22, 2021.

Subscription commitments and lock down

Acticor Biotech has undertaken to abstain from issuing equity securities for 180 calendar days following the settlement-delivery date of the Offer, subject to certain customary exceptions.

The shareholder investment funds have undertaken (i) to hold all of their existing shares for 365 days following the settlement and delivery date of the Offer, subject to certain customary exceptions, and (ii) to hold all of their newly issued shares for 180 days following the settlement and delivery date of the Offer, subject to certain customary exceptions.

Mirae has entered into a lock-up agreement for 365 days following the settlement and delivery date of the Offer, for all of its existing shares (and not the newly issued shares), subject to certain customary exceptions.

The managers have undertaken to retain all of their existing shares (including shares resulting from the exercise of warrants issued by the Company) and newly issued shares for a period of 365 calendar days following the settlement date of the Offer, subject to certain customary exceptions.

The other shareholders and holders of dilutive minority instruments have undertaken to hold all of their existing shares (including the shares resulting from the exercise of the warrants issued by the Company) for a period of 365 days following the date of settlement and delivery of the Offer, and all of the new shares for a period of 180 days following the date of settlement and delivery of the Offer, subject to certain customary exceptions.

Next steps

| | |
|-------------------------------------|--|
| 29 october 2021 | Settlement-delivery of the shares in the OPO and the Global Placement |
| 1st november 2021 | Start of trading of the Company's shares on the Euronext Growth market in Paris. |

ACTICOR share identification codes

- Name: ACTICOR
- ISIN: FR00140050J5
- Ticker: ALACT
- Sector of activity: Biotechnology

Financial intermediaries



Joint Lead Manager and Bookrunner



*Joint Lead Manager and Bookrunner
Listing Sponsor*

Availability of the Prospectus

A Prospectus, comprising (i) the Registration Document filed with the AMF on September 27, 2021 under reference number I.21-054 and (ii) a *Note d'Opération* (securities note) including a summary of the Prospectus, was approved by the AMF under number 21-446 on October 14, 2021. This Prospectus is available on the AMF's website, www.amf-france.org, and the Company's website, www.acticor-biotech.com. It is also available free of charge on request from ACTICOR BIOTECH (Hôpital Bichat – INSERM U1148, 46, rue Henri Huchard, 75018 Paris – FRANCE).

Acticor Biotech draws the attention of the public to the risk factors described in section 3 of the registration document and in section 2 of the securities note. The occurrence of one or more of these risks could have a material adverse effect on the business, reputation, financial condition, results or prospects of the Group, as well as on the market price of the shares of Acticor Biotech. The approval of the prospectus by the AMF should not be considered as a favorable opinion on the securities offered or admitted to trading.

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), that is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes. Acticor Biotech builds on the expertise and research undertaken by its co-founders Dr. Martine Jandrot-Perrus, of INSERM Paris, and Prof. Philippe Billiald, of Paris-Sud University. Acticor Biotech is a partner of the BOOSTER consortium devoted to the management and novel treatments of strokes in emergency situations. Acticor Biotech is supported by a panel of European and International Investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and the Armesa foundation).

For further information, please go to www.acticor-biotech.com

Contacts

ACTICOR BIOTECH

Gilles AVENARD
CEO
gilles.avenard@acticor-biotech.com

NewCap

Mathilde BOHIN / Olivier BRICAUD
Investor Relations
acticor@newcap.eu
Tel.: +33 (0)1 44 71 94 95

NewCap

Annie-Florence LOYER
Media Relations
afloyer@newcap.fr
Tel.: +33 (0)1 44 71 00 12

Disclaimer

This press release may not be distributed, directly or indirectly, in the United States of America, Canada, Australia, Japan or South Africa.

The release of this document may be subject to specific regulations in certain countries or constitute a breach of applicable law. Individuals in possession of this document should inform themselves of and observe any local restrictions in place. The information contained in this document does not constitute an offer of securities for sale in the United States, Canada, Australia or Japan.

No communication and no information in respect of the issue, offering and placement by the Company of its shares (the “**Shares**”) may be distributed to the public in any country where a registration or approval is required. No steps have been or will be taken outside of France in any jurisdiction where such steps would be required. The offering and subscription of the Shares may be subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility for any violation of any such restrictions by any person.

This press release constitutes a promotional communication and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and the Council of June 14th, 2017, as amended (the “**Prospectus Regulation**”). The prospectus approved by the AMF is available on the AMF website (www.amf-france.org) and the company’s website dedicated to the IPO (www.acticor-biotech.com).

The information in this press release is provided for informational purposes only and does not purport to be comprehensive and no person shall rely in any manner whatsoever on the information contained herein or its accuracy, precision or completeness. Any purchase of securities must be made solely based on the information contained in the prospectus approved by the AMF and published on the company’s and the AMF’s respective websites. Potential investors are invited to read the prospectus before making an investment decision in order to fully understand the potential risks and benefits associated with the decision to invest in the securities. The approval of the prospectus by the AMF should not be understood as an endorsement of the securities offered or admitted to trading on a regulated market.

United States of America

This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdiction (other than France). Securities may not be offered or sold in the United States unless they have been registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or are exempt from registration. The shares of Acticor Biotech have not been and will not be registered under the U.S. Securities Act and Acticor Biotech does not intend to make a public offer of its shares in the United States.

France

In France, an offer of securities to the public may only be made pursuant to a prospectus approved by the AMF.

European Economic Area and United Kingdom

With respect to the member States of the European Economic Area, other than France, and the United Kingdom, (each, a “**Relevant State**”), no action has been undertaken or will be undertaken to make an offer to the public of the shares requiring a publication of a prospectus in any Relevant State. Consequently, the securities cannot be offered and will not be offered in any Relevant State (other than France), (i) to qualified investors within the meaning of the Prospectus Regulation, for any investor in a Member State of the European Economic Area, or Regulation (EU) 2017/1129 as part of national law under the European Union (Withdrawal) Act 2018 (the “**UK Prospectus Regulation**”), for any investor in the United Kingdom, (ii) to fewer than 150 individuals or legal entities (other than qualified investors as defined in the Prospectus Regulation or the UK Prospectus Regulation, as the case may be), or (iii) in accordance with the exemptions set out in Article 1(4) of the Prospectus Regulation, or in the other case which does not require the publication by Acticor Biotech of a prospectus pursuant to the Prospectus Regulation, the UK Prospectus Regulation and/or applicable regulation in this Member States.

United Kingdom

This press release does not constitute an offer of the securities to the public in the United Kingdom. The distribution of this press release is not made, and has not been approved, by an authorized person (“authorized person”) within the meaning of Article 21(1) of the Financial Services and Markets Act 2000. As a consequence, this press release is directed only at persons who (i) are located outside the United Kingdom, (ii) have professional experience in matters relating to investments and fall within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended and (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the persons mentioned under (i), (ii) and (iii) together “**Relevant Persons**”). The securities of Acticor Biotech are directed only at Relevant Persons and no invitation, offer or agreements to subscribe, purchase or otherwise acquire the securities of Acticor Biotech may be proposed or made other than with Relevant Persons. Any person other than a Relevant Person may not act or rely on this document or any provision thereof. This press release is not a prospectus which has been approved by the Financial Conduct Authority or any other United Kingdom regulatory authority for the purposes of Section 85 of the Financial Services and Markets Act 2000.

Forward-Looking Statements

Certain information included in this press release are not historical facts but are forward-looking statements. These forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future strategy of Acticor Biotech and the environment in which Acticor Biotech operates, and involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements, or industry results or other events, to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include those set out and detailed in Chapter 3 “Risk Factors” of the registration document.

Forward-looking statements speak only as of the date of this press release and Acticor Biotech expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements included in this press release to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. Forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Acticor Biotech. Actual results could differ materially from those expressed in, or implied or projected by, forward-looking information and statements.

Information to distributors:

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“**MiFID II**”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “**MiFID II Product Governance Requirements**”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer”(for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares offered in the Offering (the “**Offered Shares**”) have been subject to a product approval process, which has determined that the Offered Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “**Target Market Assessment**”). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Offered Shares may decline and investors could lose all or part of their investment; the Offered Shares offer no guaranteed income and no capital protection; and an investment in the Offered Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment for any particular client of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Offered Shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Offered Shares and determining appropriate distribution channels.

Finally, this press release may be drafted both in French and in English. The French version of this press release shall prevail over the English version in the event of a discrepancy.